Mergerplay (Seite 12)
eröffnet am 02.11.17 21:13:52 von
neuester Beitrag 02.11.22 16:26:10 von
neuester Beitrag 02.11.22 16:26:10 von
Beiträge: 353
ID: 1.266.182
ID: 1.266.182
Aufrufe heute: 0
Gesamt: 38.415
Gesamt: 38.415
Aktive User: 0
ISIN: US30048L2034 · WKN: A3DL69
0,1860
EUR
0,00 %
0,0000 EUR
Letzter Kurs 05.10.22 L&S Exchange
Neuigkeiten
18.12.23 · Business Wire (engl.)  |
12.12.23 · Business Wire (engl.) |
12.12.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 5,4000 | +27,06 | |
| 21,440 | +23,56 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 24,000 | -20,00 | |
| 28,18 | -32,62 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 67.703.614 von PersecutorTe1 am 05.04.21 12:41:32Das Wachstum der letzten 2 Wochen ist nicht mehr sonderlich hoch. Das muss deutlich besser werden...
Ich denke die CEO Dame wird sich was einfallen lassen müssen für ihr 4 Mio Jahressalär. Das Cash reicht bis August, also nächstes Private Placement kommt dann wohl Juni/Juli. Bei nächster guter Gelegenheit plane ich auszusteigen.
Ich denke die CEO Dame wird sich was einfallen lassen müssen für ihr 4 Mio Jahressalär. Das Cash reicht bis August, also nächstes Private Placement kommt dann wohl Juni/Juli. Bei nächster guter Gelegenheit plane ich auszusteigen.
Kannst du deine eingestellten Teile auch mal kommentieren?
Sehen doch immer gleich aus?
Sehen doch immer gleich aus?
Neu von Stocktwits...
Bin nicht ganz so firm,
ist das eine gute Nachricht?
ist das eine gute Nachricht?
Evofem Biosciences Announces Closing of Public Offering of Common Stock
SAN DIEGO, March 29, 2021 /PRNewswire/ --
Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share. Evofem's aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $30.0 million. All of the shares of common stock to be sold in the offering were sold by Evofem.
Morgan Stanley and Stifel acted as joint book-running managers for the offering.
[...]
Quelle: https://finance.yahoo.com/news/evofem-biosciences-announces-…
SAN DIEGO, March 29, 2021 /PRNewswire/ --
Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share. Evofem's aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $30.0 million. All of the shares of common stock to be sold in the offering were sold by Evofem.
Morgan Stanley and Stifel acted as joint book-running managers for the offering.
[...]
Quelle: https://finance.yahoo.com/news/evofem-biosciences-announces-…
Trading Spotlight
Jetzt wird schon bei 1,60Euro geschmissen.
Auf eine bessere Zukunft.
Auf eine bessere Zukunft.
Von Stocktwits...
Irgendwie gefällt mir das Management Team nicht...
Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock
SAN DIEGO, March 24, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a price to the public of $1.75 per share. The gross proceeds from the offering to Evofem, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $30.0 million. The offering is expected to close on or about March 29, 2021, subject to satisfaction of customary closing conditions. In addition, Evofem has granted the underwriters a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Evofem.
https://evofem.investorroom.com/2021-03-24-Evofem-Bioscience…
Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock
SAN DIEGO, March 24, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a price to the public of $1.75 per share. The gross proceeds from the offering to Evofem, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $30.0 million. The offering is expected to close on or about March 29, 2021, subject to satisfaction of customary closing conditions. In addition, Evofem has granted the underwriters a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Evofem.
https://evofem.investorroom.com/2021-03-24-Evofem-Bioscience…
Wird wohl weiter runtergehen zunächst. Aktienkurs des Offering unbekannt...
Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock
March 24, 2021
https://evofem.investorroom.com/2021-03-24-Evofem-Bioscience…
Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock
March 24, 2021
https://evofem.investorroom.com/2021-03-24-Evofem-Bioscience…
Antwort auf Beitrag Nr.: 67.500.737 von iknowtheway am 17.03.21 19:47:08....hätte nix dagegen 😎😎 .. was da steht
For retail investors with stimulus money, it’s also really simple. The stock is only $2.76 and with this product, its “real value” is likely over $40.
In 2022 the Phexxi campaign will hit a new level, so you have time to get into this stock. “Get Phexxi,” its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel has already achieved significant initial results.
The “Get Phexxi” DTC commercial garnered over 173 million views in just the first three weeks following the campaign launch on Valentine’s Day.
A 73% increase in monthly ex-factory sales of Phexxi (unit shipments from warehouse to wholesalers, each containing 12 single-dose Phexxi applicators) in February 2021.
Ex-factory sales for the first quarter of 2021 exceeded levels for full-year 2020 by March 12, 2021, with over 9,100 units shipped quarter-to-date.
Millennial and GenZ women will also prefer a non-hormonal method of birth control that’s not really invasive. The stock was more than double what it is today one year ago. The five year chart shows the stock has a habit of reaching as high as $12. But if the Phexxi product takes off, the stock could easily surpass $20, reaching at peak around $45.
For retail investors with stimulus money, it’s also really simple. The stock is only $2.76 and with this product, its “real value” is likely over $40.
In 2022 the Phexxi campaign will hit a new level, so you have time to get into this stock. “Get Phexxi,” its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel has already achieved significant initial results.
The “Get Phexxi” DTC commercial garnered over 173 million views in just the first three weeks following the campaign launch on Valentine’s Day.
A 73% increase in monthly ex-factory sales of Phexxi (unit shipments from warehouse to wholesalers, each containing 12 single-dose Phexxi applicators) in February 2021.
Ex-factory sales for the first quarter of 2021 exceeded levels for full-year 2020 by March 12, 2021, with over 9,100 units shipped quarter-to-date.
Millennial and GenZ women will also prefer a non-hormonal method of birth control that’s not really invasive. The stock was more than double what it is today one year ago. The five year chart shows the stock has a habit of reaching as high as $12. But if the Phexxi product takes off, the stock could easily surpass $20, reaching at peak around $45.
Durchsuchen
